Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 17NETWORK 4NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Colorectal Neoplasms 114Neoplasms 37Neoplasm Metastasis 24Stomach Neoplasms 22Pancreatic Neoplasms 19Colonic Neoplasms 15Rectal Neoplasms 13Esophageal Squamous Cell Carcinoma 13Sarcoma 10Esophageal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Small Cell Lung Carcinoma 8Sarcoma, Ewing 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Ovarian Neoplasms 6Gastrointestinal Neoplasms 6Uterine Cervical Neoplasms 5Solid Tumors 5Recurrence 5Neuroblastoma 5Intestinal Neoplasms 5Digestive System Neoplasms 5Cholangiocarcinoma 5Advanced Solid Tumor 5Rhabdomyosarcoma 4Gastrointestinal Diseases 4Endometrial Neoplasms 4Digestive System Diseases 4

Interventions

Temozolomide 3Irinotecan 3tozuleristide 2selpercatinib 2lenvatinib 2gadobenic acid 2avelumab 2Radiation 2Paclitaxel 2Leflunomide 2Immunotherapy 2Gemcitabine 2Everolimus 2Cisplatin 2Carboplatin 2Cancer Vaccines 2Bevacizumab 2Adjuvants, Immunologic 2ridaforolimus 1regorafenib 1prinomastat 1pomalidomide 1perillyl alcohol 1pemigatinib 1pembrolizumab 1pamiparib 1omburtamab I-131 1irinotecan sucrosofate 1interferon gamma-1b 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Central Nervous System Neoplasms × Irinotecan × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

NCT04525014 2024-10-31

PIRATE

EpicentRx, Inc.

Phase 1 Terminated
2 enrolled
CNS

Brain Neoplasms, Neoplasms, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT00562419 2010-10-27

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 2 Unknown
72 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡